Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOVER-WaM CLR 131 in Relapsed or Refractory Waldenstrom Macroglobulinemia
2023-508671-37-00Phase 2Authorised
- Sponsor
- Cellectar Biosciences
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of Iopofosine I-131 in Waldenström macroglobulinemia (WM), Lymphoplasmacytic Lymphoma (LPL) and B-cell malignancy, sponsored by Cellectar Biosciences. Primary endpoint: Major response rate (MRR). Planned start Jul 2024; status: authorised.
02
Drugs
Iopofosine I-131
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)B-cell malignancy
Beyond the preview
Go deeper on 2023-508671-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508671-37-00.